• Je něco špatně v tomto záznamu ?

MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty

M. Hromadka, Z. Motovska, O. Hlinomaz, P. Kala, F. Tousek, J. Jarkovsky, M. Beranova, P. Jansky, M. Svoboda, I. Krepelkova, R. Rokyta, P. Widimsky, M. Karpisek

. 2021 ; 11 (6) : . [pub] 20210604

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024610

Grantová podpora
CZ.01.1.02/0.0/0.0/16_084/0008832 Ministerstvo Průmyslu a Obchodu
P35 and Q38 Univerzita Karlova v Praze

Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07-119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40-7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03-0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17-0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024610
003      
CZ-PrNML
005      
20211013133840.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jpm11060508 $2 doi
035    __
$a (PubMed)34199723
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hromadka, Milan $u Department of Cardiology, University Hospital and Faculty of Medicine in Pilsen, Charles University, 304 60 Pilsen, Czech Republic
245    10
$a MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty / $c M. Hromadka, Z. Motovska, O. Hlinomaz, P. Kala, F. Tousek, J. Jarkovsky, M. Beranova, P. Jansky, M. Svoboda, I. Krepelkova, R. Rokyta, P. Widimsky, M. Karpisek
520    9_
$a Aim. This study was designed to evaluate the relationship between microRNAs (miRNAs), miR-126-3p and miR-223-3p, as new biomarkers of platelet activation, and predicting recurrent thrombotic events after acute myocardial infarction (AMI). Methods and Results. The analysis included 598 patients randomized in the PRAGUE-18 study (ticagrelor vs. prasugrel in AMI). The measurements of miRNAs were performed by using a novel miRNA immunoassay method. The association of miRNAs with the occurrence of the ischemic endpoint (EP) (cardiovascular death, nonfatal MI, or stroke) and bleeding were analyzed. The miR-223-3p level was significantly related to an increased risk of occurrence of the ischemic EP within 30 days (odds ratio (OR) = 15.74, 95% confidence interval (CI): 2.07-119.93, p = 0.008) and one year (OR = 3.18, 95% CI: 1.40-7.19, p = 0.006), respectively. The miR-126-3p to miR-223-3p ratio was related to a decreased risk of occurrence of EP within 30 days (OR = 0.14, 95% CI: 0.03-0.61, p = 0.009) and one year (OR = 0.37, 95% CI: 0.17-0.82, p = 0.014), respectively. MiRNAs were identified as independent predictors of EP even after adjustment for confounding clinical predictors. Adding miR-223-3p and miR-126-3p to miR-223-3p ratios as predictors into the model calculating the ischemic risk significantly increased the predictive accuracy for combined ischemic EP within one year more than using only clinical ischemic risk parameters. No associations between miRNAs and bleeding complications were identified. Conclusion. The miR-223-3p and the miR-126-3p are promising independent predictors of thrombotic events and can be used for ischemic risk stratification after AMI.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Motovska, Zuzana $u Cardiocentre, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic
700    1_
$a Hlinomaz, Ota $u First Department of Internal Medicine-Cardioangiology, International Clinical Research Center, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, 656 91 Brno, Czech Republic
700    1_
$a Kala, Petr $u Department of Internal Medicine and Cardiology, University Hospital and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a Tousek, Frantisek $u Cardiocentre-Department of Cardiology, Regional Hospital, 370 01 Ceske Budejovice, Czech Republic
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses at the Faculty of Medicine and the Faculty of Science, Masaryk University, 602 00 Brno, Czech Republic
700    1_
$a Beranova, Marketa $u First Department of Internal Medicine-Cardioangiology, International Clinical Research Center, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, 656 91 Brno, Czech Republic
700    1_
$a Jansky, Pavel $u Department of Anestesiology and Resuscitation, University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic
700    1_
$a Svoboda, Michal $u Institute of Biostatistics and Analyses at the Faculty of Medicine and the Faculty of Science, Masaryk University, 602 00 Brno, Czech Republic
700    1_
$a Krepelkova, Iveta $u BioVendor-Laboratory Medicine, 621 00 Brno, Czech Republic $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, 621 00 Brno, Czech Republic
700    1_
$a Rokyta, Richard $u Department of Cardiology, University Hospital and Faculty of Medicine in Pilsen, Charles University, 304 60 Pilsen, Czech Republic
700    1_
$a Widimsky, Petr $u Cardiocentre, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, 100 34 Prague, Czech Republic
700    1_
$a Karpisek, Michal $u BioVendor-Laboratory Medicine, 621 00 Brno, Czech Republic $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, 621 00 Brno, Czech Republic
773    0_
$w MED00203320 $t Journal of personalized medicine $x 2075-4426 $g Roč. 11, č. 6 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34199723 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013133837 $b ABA008
999    __
$a ind $b bmc $g 1708397 $s 1145107
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 6 $e 20210604 $i 2075-4426 $m Journal of personalized medicine $n J. pers. med. $x MED00203320
GRA    __
$a CZ.01.1.02/0.0/0.0/16_084/0008832 $p Ministerstvo Průmyslu a Obchodu
GRA    __
$a P35 and Q38 $p Univerzita Karlova v Praze
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

    Možnosti archivace